HK1161114A1 - Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms l- - Google Patents

Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms l-

Info

Publication number
HK1161114A1
HK1161114A1 HK12101886.1A HK12101886A HK1161114A1 HK 1161114 A1 HK1161114 A1 HK 1161114A1 HK 12101886 A HK12101886 A HK 12101886A HK 1161114 A1 HK1161114 A1 HK 1161114A1
Authority
HK
Hong Kong
Prior art keywords
carnitine
neoplasms
alkanoyl
treatment
combination
Prior art date
Application number
HK12101886.1A
Other languages
English (en)
Chinese (zh)
Inventor
．卡瓦扎
．卡米納迪
．皮薩諾
Original Assignee
希格馬托製藥工業公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 希格馬托製藥工業公司 filed Critical 希格馬托製藥工業公司
Publication of HK1161114A1 publication Critical patent/HK1161114A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12101886.1A 2008-12-01 2012-02-24 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms l- HK1161114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170331 2008-12-01
US24854309P 2009-10-05 2009-10-05
PCT/EP2009/066113 WO2010063696A1 (en) 2008-12-01 2009-12-01 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms

Publications (1)

Publication Number Publication Date
HK1161114A1 true HK1161114A1 (en) 2012-08-24

Family

ID=40445249

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101886.1A HK1161114A1 (en) 2008-12-01 2012-02-24 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms l-

Country Status (11)

Country Link
US (2) US20120208883A1 (ja)
EP (2) EP2352496A1 (ja)
JP (2) JP2012510498A (ja)
KR (1) KR20110089402A (ja)
CN (1) CN102215838B (ja)
AU (1) AU2009324183A1 (ja)
CA (1) CA2740347A1 (ja)
EA (1) EA201170732A1 (ja)
HK (1) HK1161114A1 (ja)
MX (1) MX2011005593A (ja)
WO (2) WO2010063696A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp ｐ２１発現促進剤
CN101967125B (zh) * 2010-10-08 2012-07-04 广州暨南生物医药研究开发基地有限公司 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用
ES2392879B1 (es) * 2011-05-31 2013-11-04 Servicio Andaluz De Salud Composiciones y preparaciones combinadas de sunitinib y l-carnitina
WO2014061639A1 (ja) * 2012-10-15 2014-04-24 旭硝子株式会社 複層ガラスおよび複層ガラスの製造方法
CN105753921B (zh) * 2016-03-31 2019-08-30 沈阳药科大学 基于肠道octn2载体蛋白设计的前药及其制备方法
CN114470216A (zh) * 2020-10-23 2022-05-13 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法
CN114522158B (zh) * 2022-01-21 2023-06-27 武汉大学 用于制备治疗肝癌药物的代谢物及其应用
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
US20030199535A1 (en) * 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
PT1100589E (pt) * 1998-07-30 2005-05-31 Sigma Tau Ind Farmaceuti Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena
IT1302289B1 (it) * 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica

Also Published As

Publication number Publication date
AU2009324183A1 (en) 2010-06-10
US20120093809A1 (en) 2012-04-19
WO2010063698A1 (en) 2010-06-10
KR20110089402A (ko) 2011-08-08
CN102215838A (zh) 2011-10-12
JP2015098481A (ja) 2015-05-28
EP2361086A1 (en) 2011-08-31
MX2011005593A (es) 2011-06-20
EA201170732A1 (ru) 2011-12-30
JP2012510498A (ja) 2012-05-10
CN102215838B (zh) 2014-06-18
US20120208883A1 (en) 2012-08-16
CA2740347A1 (en) 2010-06-10
WO2010063696A1 (en) 2010-06-10
EP2352496A1 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
HK1161114A1 (en) Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms l-
IL249941A0 (en) Spiro-oxaindole substances and medical preparations containing them
GB0810203D0 (en) Cannaboids in combination with non-cannabinoid chemotherapeutic agents
IL206819A0 (en) Pyrrolopyrimidines and pyrrolopyridines
PL3031948T3 (pl) Korpus powlekany twardym materiałem
PL2250299T3 (pl) Ciało powleczone materiałem twardym
GB0818241D0 (en) Compounds and their use
GB0803018D0 (en) Therapeutic compounds and their use
PT1978947E (pt) Derivados nitro-óxido para utilização no tratamento de distrofias musculares
IL208081A0 (en) Amido - thiophene compounds and their use
ZA201007395B (en) Aryl-quinolyl compounds and their use
PL2344449T3 (pl) Związki arylo-fenylo-sulfonamido-cykloalkilowe i ich zastosowanie
EP2307052A4 (en) ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
ZA201102690B (en) Amide compounds useful in therapy
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0812913D0 (en) Therapeutic compounds and their use
PT2136631E (pt) Processos para tratamento da neoplasia com associação de agentes quimioterapêuticos e radiação
GB0801319D0 (en) Compounds and their use
GB0802128D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
GB0819103D0 (en) Raphaine compounds and their use in therapy
BRPI0922155A2 (pt) uso de alcanoil l-carnitina em combinação com agentes quimioterápicos para o tratamento de neoplasias
GB0802195D0 (en) Compounds and their use II
GB0802194D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171201